SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Wasay Mohammad)
 

Search: WFRF:(Wasay Mohammad) > (2023) > Direct oral anticoa...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Direct oral anticoagulants for the treatment of cerebral venous thrombosis - a protocol of an international phase IV study

van de Munckhof, Anita (author)
van Kammen, Mayte Sanchez (author)
Krzywicka, Katarzyna (author)
show more...
Aaron, Sanjith (author)
de Sousa, Diana Aguiar (author)
Antochi, Florina (author)
Arauz, Antonio (author)
Barboza, Miguel A. (author)
Conforto, Adriana B. (author)
Dentali, Francesco (author)
Contreras, Daniel Galdames (author)
Ji, Xunming (author)
Jood, Katarina, 1966 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience
Heldner, Mirjam R. (author)
Hernandez-Perez, Maria (author)
Kam, Wayneho (author)
Kleinig, Timothy J. (author)
Kristoffersen, Espen S. (author)
Leker, Ronen R. (author)
Lemmens, Robin (author)
Poli, Sven (author)
Yesilot, Niluefer (author)
Wasay, Mohammad (author)
Wu, Teddy Y. (author)
Arnold, Marcel (author)
Lucas-Neto, Lia (author)
Middeldorp, Saskia (author)
Putaala, Jukka (author)
Tatlisumak, Turgut (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience
Ferro, Jose M. (author)
Coutinho, Jonathan M. (author)
show less...
 (creator_code:org_t)
2023
2023
English.
In: FRONTIERS IN NEUROLOGY. - 1664-2295. ; 14
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Introduction: Current guidelines recommend that patients with cerebral venous thrombosis (CVT) should be treated with vitamin K antagonists (VKAs) for 3-12 months. Direct oral anticoagulants (DOACs), however, are increasingly used in clinical practice. An exploratory randomized controlled trial including 120 patients with CVT suggested that the efficacy and safety profile of dabigatran (a DOAC) is similar to VKAs for the treatment of CVT, but large-scale prospective studies from a real-world setting are lacking.Methods: DOAC-CVT is an international, prospective, observational cohort study comparing DOACs to VKAs for the prevention of recurrent venous thrombotic events after acute CVT. Patients are eligible if they are 18 years or older, have a radiologically confirmed CVT, and have started oral anticoagulant treatment (DOAC or VKA) within 30 days of CVT diagnosis. Patients with an absolute contra-indication for DOACs, such as pregnancy or severe renal insufficiency, are excluded from the study. We aim to recruit at least 500 patients within a three-year recruitment period. The primary endpoint is a composite of recurrent venous thrombosis and major bleeding at 6 months of follow-up. We will calculate an adjusted odds ratio for the primary endpoint using propensity score inverse probability treatment weighting.Discussion: DOAC-CVT will provide real-world data on the comparative efficacy and safety of DOACs versus VKAs for the treatment of CVT.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

cerebral venous thrombosis
anticoagulants
DOAC
vitamin K antagonist
treatment

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view